Toxicological relevance of pharmaceuticals in drinking water.

Interest in the public health significance of trace levels of pharmaceuticals in potable water is increasing, particularly with regard to the effects of long-term, low-dose exposures. To assess health risks and establish target concentrations for water treatment, human health risk-based screening levels for 15 pharmaceutically active ingredients and four metabolites were compared to concentrations detected at 19 drinking water treatment plants across the United States. Compounds were selected based on rate of use, likelihood of occurrence, and potential for toxicity. Screening levels were established based on animal toxicity data and adverse effects at therapeutic doses, focusing largely on reproductive and developmental toxicity and carcinogenicity. Calculated drinking water equivalent levels (DWELs) ranged from 0.49 microg/L (risperidone) to 20,000 microg/L (naproxen). None of the 10 detected compounds exceeded their DWEL. Ratios of DWELs to maximum detected concentrations ranged from 110 (phenytoin) to 6,000,000 (sulfamethoxazole). Based on this evaluation, adverse health effects from targeted pharmaceuticals occurring in U.S. drinking water are not expected.

[1]  T. Ternes,et al.  Pharmaceuticals and personal care products in the environment: agents of subtle change? , 1999, Environmental health perspectives.

[2]  E. Thurman,et al.  Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. , 2002, Environmental science & technology.

[3]  Erin M. Snyder,et al.  Pharmaceuticals and personal care products in the waters of Lake Mead, Nevada , 2001 .

[4]  G. Huschek,et al.  Environmental risk assessment of medicinal products for human use according to European Commission recommendations , 2004, Environmental toxicology.

[5]  Simon Webb,et al.  Indirect human exposure to pharmaceuticals via drinking water. , 2003, Toxicology letters.

[6]  E. McGuire,et al.  Carcinogen bioassay and mutagenicity studies with the hypolipidemic agent gemfibrozil. , 1981, Journal of the National Cancer Institute.

[7]  Brett J. Vanderford,et al.  Analysis of endocrine disruptors, pharmaceuticals, and personal care products in water using liquid chromatography/tandem mass spectrometry. , 2003, Analytical chemistry.

[8]  Arun Kumar,et al.  Human health risk assessment of pharmaceuticals in water: an uncertainty analysis for meprobamate, carbamazepine, and phenytoin. , 2010, Regulatory toxicology and pharmacology : RTP.

[9]  Joel P Bercu,et al.  Human health risk assessments for three neuropharmaceutical compounds in surface waters. , 2008, Regulatory toxicology and pharmacology : RTP.

[10]  M. Reinhard,et al.  Occurrence and fate of pharmaceuticals and alkylphenol ethoxylate metabolites in an effluent‐dominated river and wetland , 2004, Environmental toxicology and chemistry.

[11]  A. Collier.  Pharmaceutical Contaminants in Potable Water: Potential Concerns for Pregnant Women and Children , 2007, EcoHealth.

[12]  A. V. van Wezel,et al.  Toxicological relevance of emerging contaminants for drinking water quality. , 2010, Water research.

[13]  D. Bitrán,et al.  Sexually dimorphic influence of prenatal exposure to diazepam on behavioral responses to environmental challenge and on gamma-aminobutyric acid (GABA)-stimulated chloride uptake in the brain. , 1991, The Journal of pharmacology and experimental therapeutics.

[14]  M. Morgan,et al.  Antibiotic Resistance of Gram-Negative Bacteria in Rivers, United States , 2002, Emerging infectious diseases.

[15]  Edward V. Sargent,et al.  A Human Health Risk Assessment of Pharmaceuticals in the Aquatic Environment , 2002 .

[16]  Jerry E. Ongerth,et al.  Drug Residuals: How Xenobiotics can Affect Water Supply Sources , 2004 .

[17]  Ettore Zuccato,et al.  Presence of therapeutic drugs in the environment , 2000, The Lancet.

[18]  V. Cunningham,et al.  Human health risk assessment from the presence of human pharmaceuticals in the aquatic environment. , 2009, Regulatory toxicology and pharmacology : RTP.

[19]  Mark J. Reasor,et al.  Principles of Toxicology , 2003 .

[20]  Benjamin D. Stanford,et al.  Pharmaceuticals and endocrine disrupting compounds in U.S. drinking water. , 2009, Environmental science & technology.

[21]  T. Tuhkanen,et al.  Seasonal variation in the occurrence of pharmaceuticals in effluents from a sewage treatment plant and in the recipient water. , 2005, Environmental science & technology.

[22]  J. C. Durán-Alvarez,et al.  The analysis of a group of acidic pharmaceuticals, carbamazepine, and potential endocrine disrupting compounds in wastewater irrigated soils by gas chromatography-mass spectrometry. , 2009, Talanta.

[23]  C. Kimmel,et al.  Adverse pregnancy outcomes associated with maternal enalapril antihypertensive treatment , 2003, Pharmacoepidemiology and drug safety.

[24]  J. Palermo-neto,et al.  Developmental, neuro and immunotoxic effects of perinatal diazepam treatment in rats. , 1999, Immunopharmacology and immunotoxicology.

[25]  D. Kolpin,et al.  Pharmaceuticals and Other Organic Waste Water Contaminants Within a Leachate Plume Downgradient of a Municipal Landfill , 2004 .

[26]  Alden K Henderson,et al.  Persistence of pharmaceutical compounds and other organic wastewater contaminants in a conventional drinking-water-treatment plant. , 2004, The Science of the total environment.

[27]  G. Foster,et al.  Tracking acidic pharmaceuticals, caffeine, and triclosan through the wastewater treatment process , 2005, Environmental toxicology and chemistry.

[28]  Gregory A Loraine,et al.  Seasonal variations in concentrations of pharmaceuticals and personal care products in drinking water and reclaimed wastewater in southern California. , 2006, Environmental science & technology.

[29]  D W Gaylor,et al.  Regulatory cancer risk assessment based on a quick estimate of a benchmark dose derived from the maximum tolerated dose. , 1998, Regulatory toxicology and pharmacology : RTP.

[30]  Jacob Gibs,et al.  Efficiency of conventional drinking-water-treatment processes in removal of pharmaceuticals and other organic compounds. , 2007, The Science of the total environment.

[31]  F. Christensen.  Pharmaceuticals in the environment--a human risk? , 1998, Regulatory toxicology and pharmacology : RTP.

[32]  Martin Kampmann,et al.  Ozonation: a tool for removal of pharmaceuticals, contrast media and musk fragrances from wastewater? , 2003, Water research.

[33]  P. Dalén,et al.  Formation of meprobamate from carisoprodol is catalysed by CYP2C19. , 1996, Pharmacogenetics.

[34]  P. Anderson,et al.  Human pharmaceuticals in US surface waters: a human health risk assessment. , 2005, Regulatory toxicology and pharmacology : RTP.

[35]  G. Trenholme,et al.  Comparative in vitro activity of ciprofloxacin against Campylobacter spp. and other bacterial enteric pathogens , 1984, Antimicrobial Agents and Chemotherapy.

[36]  Jordi Mas,et al.  Potential chemical and microbiological risks on human health from urban wastewater reuse in agriculture. Case study of wastewater effluents in Spain , 2010, Journal of environmental science and health. Part. B, Pesticides, food contaminants, and agricultural wastes.